Avid Bioservices Inc (CDMO)

[entdoc]

nuke, all is evolving and especially competition. Rhodanine compounds have been known for years to be pharmacologically active, so variations of the molecule are a logical pursuit.
What would make me uneasy about the UCLA compound is the relative lack of specificity by which it attaches to and damages both normal and viral cells, and the damage done to normal cells may be repaired by the cell whereas damage done to a static viral cell membrane may not be. This one has a ways to go. However, it is not in the cards that Bavi will be the last and only agent developed to fight pathogenic enveloped viruses. Actually I am amazed that Bavi and Cotara are still in the forefront of anticancer and antiviral attack. Something to think about for those out there that think things move slowly at PPHM...